Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Immunogenic cell death, including necroptosis, can enhance anti-tumor immune responses.
• Receptor-interacting serine/threonine protein kinase 3 (RIPK3) signaling is crucial for necroptosis and immune activation in solid tumors.
• The therapeutic potential of RIPK3 manipulation in B cell malignancies is largely unexplored.

Purpose of the Study:

• To investigate the role of RIPK3 signaling in B cell malignancies.
• To develop a strategy for manipulating RIPK3 activity to promote immune-mediated tumor control in B cell cancers.

Main Methods:

• Utilized intravital imaging to monitor and control RIPK3 signaling in malignant B cells.
• Investigated RIPK3-induced cell death pathways, including apoptosis and necroptosis.
• Employed combination therapy involving RIPK3 activation, caspase inhibition, and type I interferon.

Main Results:

• RIPK3 activation in B cells induced apoptosis and macrophage engulfment but not necroptosis due to low MLKL expression.
• Co-treatment with type I interferon and caspase inhibitors successfully redirected RIPK3-induced cell death towards necroptosis.
• The combination therapy demonstrated significant immune-mediated control of B cell tumors.

Conclusions:

• Reprogramming RIPK3 activity is a viable strategy for targeting B cell malignancies.
• Combination therapy modulating RIPK3 signaling offers a promising approach for enhancing anti-tumor immunity in B cell cancers.